Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Manchester United PLC (MANU) Price & Performance

AbCellera Biologics IncTrade
Manchester United PLCTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Manchester United PLC — how do they compare? AbCellera Biologics Inc trades at $10.35 (market cap $2.99B), while Manchester United PLC trades at $22.23 (market cap $3.80B). The key difference: Manchester United PLC is the larger of the two by market cap, and Manchester United PLC pays a 1.26% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLMANU
Market Cap
$2.99B$3.80B
Sector
HealthMedia
52-Week High
$9.76$23.53
52-Week Low
$2.78$15.10
Enterprise Value
$2.58B$4.74B
Dividend Yield
1.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.

The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.

Manchester United PLC

Manchester United (MANU) trades at $22.88, up 5.44% on the day, with a bearish technical signal. The company reported a net loss of $33.02M for 2025, though revenue grew to $666.51M. Recent news highlights the acquisition of land for a new 100,000-seat stadium as a significant long-term de-risking milestone. Cash flow from operations remains positive at $72.70M, but negative profitability metrics and high debt levels persist.

The outlook is mixed; stadium development and Champions League qualification offer growth catalysts, but consistent net losses and weak margins pose fundamental risks. Analyst consensus is neutral with a 60% hold rating. The stock's trajectory hinges on successful execution of cost reductions and capitalizing on new revenue streams from the stadium project.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Manchester United PLC

Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.

Read more on MANU